Open AccessPlasminogen activator inhibitor‐1 as a potential marker for the malignancy of gastric cancer
Author(s) -
Sakakibara Takumi,
Hibi Kenji,
Koike Masahiko,
Fujiwara Michitaka,
Kodera Yasuhiro,
Ito Katsuki,
Nakao Akimasa
Publication year - 2006
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/j.1349-7006.2006.00185.x
Subject(s) - malignancy , cancer , plasminogen activator inhibitor 1 , metastasis , plasminogen activator , medicine , oncology , gastroenterology , cancer research , pathology
To test the hypothesis that plasminogen activator inhibitor‐1 (PAI‐1) may serve as a candidate marker for the malignancy of gastric cancer, we carried out quantitative reverse transcription–polymerase chain reaction for the PAI‐1 gene and evaluated the possible relationship between PAI‐1 gene expression levels and clinicopathological findings in gastric cancer. A significant increase in PAI‐1 expression scores was observed in lymph node metastasis‐positive gastric cancers (2.11 ± 0.35) compared to metastasis‐negative cancers (0.33 ± 0.49) ( P = 0.0048), as well as in distant metastasis‐positive gastric cancers (3.68 ± 0.58) compared to metastasis‐negative cancers (1.20 ± 0.32). The PAI‐1 expression score markedly increased with tumor stage ( P < 0.0001; ANOVA test). Moreover, multivariate analysis revealed the PAI‐1 expression score to be a strong and independent prognostic factor for gastric cancer ( P = 0.0450). These results suggested that PAI‐1 might serve as a new and promising parameter for the prediction of prognosis in gastric cancer. ( Cancer Sci 2006; 97)